SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

ELVN

Enliven Therapeutics, Inc.
NASDAQHealth Care

Latest close: 37.32 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Oct 14, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  2. Oct 1, 2026Reported sale · Form 4J. Scott Garland · $606.7KOpen the filing ↗
  3. Oct 1, 2026Notice of sale · Form 144JEFFREY GARLAND · Director · $606.7KOpen the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record76327 flagged findings
Reported transactions (Form 4)80since Aug 27, 2025 · and 8 other holdings
Corporate events (8-K)30since Jun 11, 2021

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

Identity

Formerly traded as IMRA.

SEC topics

Regulatory history

Topics detected in its SEC reports, with the original excerpt.

Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.

  • 2026-06-12share offering or dilution eventrecentOpen filing ↗
    “…stock issuable upon exercise of each Pre-Funded Warrant are subject to appropriate adjustments in the event of certain stock…”
    +1 more passage from the same document
    • “…is exercisable, in the holder’s discretion, by (i) payment in full in immediately available funds for the number of shares of…”
  • 2026-06-12share offering or dilution eventrecentOpen filing ↗
    “…August 13, 2025) 8,933,334 Shares of Common Stock Pre-Funded Warrants to Purchase 1,733,333 Shares of Common Stock We are offering…”
    +1 more passage from the same document
    • “…stock to investors that so choose, pre-funded warrants to purchase up to 1,733,333 shares of our common stock in this offering.…”
  • 2026-06-12capital return (buybacks/dividends)recentOpen filing ↗
    “…where the securities of such series may be surrendered for registration of transfer or exchange, and where notices and demands to us…”
    +1 more passage from the same document
    • “…to an agreement or equity awards granted under a stock incentive plan or other equity award plan, each such agreement or plan…”
  • 2026-06-12merger or acquisition eventrecentOpen filing ↗
    “…FDA, including at a planned End-of-Phase 2 meeting anticipated in the third quarter of 2026. Corporate Information Enliven Inc.…”
    +1 more passage from the same document
    • “…solve complex medicinal chemistry problems in a target- and indication-agnostic approach. Corporate Information Enliven Inc.…”
  • 2026-06-12reverse splitrecentOpen filing ↗
    “…a Delaware corporation and our wholly owned subsidiary (“Merger Sub”), pursuant to which, among other matters, Merger Sub merged…”
  • 2026-06-11share offering or dilution eventrecentOpen filing ↗
    “…dated August 13, 2025) $250,000,000 Shares of Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock We are…”
    +1 more passage from the same document
    • “…of common stock to investors that so choose, pre-funded warrants to purchase up to shares of our common stock in this offering.…”
  • 2026-06-11capital return (buybacks/dividends)recentOpen filing ↗
    “…where the securities of such series may be surrendered for registration of transfer or exchange, and where notices and demands to us…”
    +1 more passage from the same document
    • “…to an agreement or equity awards granted under a stock incentive plan or other equity award plan, each such agreement or plan…”
  • 2026-06-11merger or acquisition eventrecentOpen filing ↗
    “…FDA, including at a planned End-of-Phase 2 meeting anticipated in the third quarter of 2026. Corporate Information Enliven Inc.…”
    +1 more passage from the same document
    • “…solve complex medicinal chemistry problems in a target- and indication-agnostic approach. Corporate Information Enliven Inc.…”

1 older entry not shown

Original excerpts from SEC filings, untranslated. Not advice and not a prediction.

Reverse splits in 5 years

1 reverse split in 5 years (1:4 on Feb 24, 2023) · 1:4 cumulative

The other times: of 818 securities that did their first reverse split in 5 years, a year later the median was worth 0.53× the price on the day of the split; 382 lost more than half and 209 rose (809 with a price a year later).

Our own series, not the whole market: based on the splits we have on record (provider and SEC); an unrecorded one does not count. Historical distribution, not a prediction.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 763)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Oct 16, 26Form 4 ↗Insider transaction new
  • Oct 16, 26Form 3 ↗Insider transaction new
  • Oct 14, 268-K ↗Current report · A senior executive left or was appointed new
  • Oct 5, 26Form 4 ↗Insider transaction
  • Oct 1, 26Form 144 ↗Notice of proposed sale
  • Insider transaction · 2 Form 4 filingsshow all 2hide
  • Notice of proposed sale · 2 Form 144 filingsshow all 2hide
  • Insider transaction · 3 Form 4 filingsshow all 3hide
  • Aug 6, 26SCHEDULE 13G/A ↗Passive stake · FMR LLC · 15.0% · event on Jun 30, 26 · amendment
  • Aug 5, 2610-Q ↗Quarterly report
  • Aug 5, 268-K ↗Current report · Results
  • Aug 4, 26Form 144 ↗Notice of proposed sale
  • Insider transaction · 2 Form 4 filingsshow all 2hide
  • Jul 17, 26Form 144 ↗Notice of proposed sale
  • Insider transaction · 2 Form 4 filingsshow all 2hide
  • Jun 24, 26SCHEDULE 13D/A ↗Stake with intent to influence · ORBIMED ADVISORS LLC · 9.5% · event on Jun 22, 26 · amendment
  • Insider transaction · 2 Form 4 filingsshow all 2hide
  • Jun 22, 26SCHEDULE 13G/A ↗Passive stake · Polar Capital Holdings Plc · 8.5% · event on Mar 31, 26 · amendment

763 filings on record, the oldest from Sep 11, 19.

Listing the 25 most recent filings of the 763 on record.

8-Ks, explained

Stress1Structure17Governance14
  • Oct 14, 26GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Jun 12, 26StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Jan 7, 26GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Dec 11, 25GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Jun 16, 25StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Governance3 senior executive changes2024show all 3hide
    • Jun 18, 24GovernanceA senior executive left or was appointed+3 more in the same filing8-K 5.02 ↗
    • May 29, 24GovernanceA senior executive left or was appointed8-K/A 5.02 ↗
    • Apr 9, 24GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Mar 19, 24StructureEntered a material agreement+3 more in the same filing8-K 1.01 ↗
  • Jun 26, 23StructureA material agreement was terminated+2 more in the same filing8-K 1.02 ↗
  • Mar 1, 23StructureEntered a material agreement+9 more in the same filing8-K 1.01 ↗
  • Feb 22, 23GovernanceA senior executive left or was appointed+5 more in the same filing8-K 5.02 ↗
  • Nov 10, 22StructureCompleted an acquisition or disposal+2 more in the same filing8-K 2.01 ↗
  • Structure3 material agreements entered2022show all 3hide
    • Oct 13, 22StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
    • Sep 7, 22StructureEntered a material agreement+3 more in the same filing8-K 1.01 ↗
    • Jul 29, 22StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗

4 older filings not shown · The record reaches back to Apr 23, 20.

Notable in the record

Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.

  • Apr 14, 22StressRestructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗

The full record holds 1 stress filing.

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13D: stake and stated purpose

Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.

  • ORBIMED ADVISORS LLC9.5%Jun 22, 26SCHEDULE 13D/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • FMR LLC15.0%Jun 30, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • Polar Capital Holdings Plc8.5%Mar 31, 26SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 3 earlier filings
  • Commodore Capital LP7.7%Mar 31, 26SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • Vestal Point Capital, LP5.4%Mar 31, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • BlackRock, Inc.5.1%Jun 30, 25SCHEDULE 13G/A ↗
show 2 more holdershide
  • Fairmount Funds Management LLC3.1%Mar 31, 26SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • Venrock Healthcare Capital Partners III, L.P.2.8%Mar 31, 26SCHEDULE 13G/A ↗7 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

Sale intention announced

On Oct 1, JEFFREY GARLAND filed notice of intent to sell up to $607K. That is about 0.02% of shares outstanding.

A notice is not a sale: it may not go ahead, may happen in part, or at a different price.

After the notice, they sold $607K on Oct 1, per their Form 4. That is 100% of the shares announced so far, and the window is still open.

View notice (Form 144) ↗+7 more recent notices · 4 with a later sale

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Oct 1, 26Sell$607KJ. Scott Garland↗
  • Sep 17, 26Sell$146KHelen Louise CollinsCHIEF MEDICAL OFFICER↗
  • Sep 17, 26Sell$94KHelen Louise CollinsCHIEF MEDICAL OFFICER↗
  • Sep 17, 26Sell$12KHelen Louise CollinsCHIEF MEDICAL OFFICER↗
  • Sep 17, 26Sell$177KBenjamin HohlCHIEF FINANCIAL OFFICER↗
  • Sep 17, 26Sell$111KBenjamin HohlCHIEF FINANCIAL OFFICER↗
  • Sep 17, 26Sell$15KBenjamin HohlCHIEF FINANCIAL OFFICER↗
  • Aug 17, 26Sell$228KHelen Louise CollinsCHIEF MEDICAL OFFICER↗
  • Aug 17, 26Sell$65KHelen Louise CollinsCHIEF MEDICAL OFFICER↗
  • Aug 17, 26Sell$270KBenjamin HohlCHIEF FINANCIAL OFFICER↗
  • Aug 17, 26Sell$82KBenjamin HohlCHIEF FINANCIAL OFFICER↗
  • Aug 4, 26Sell$9.6MMika K Derynck↗

There are 17 more transactions in this stretch.

Stock compensation, tax and giftsshow the 11 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Oct 1, 26Compensation$201KJ. Scott Garland↗
  • Sep 17, 26Compensation$12KHelen Louise CollinsCHIEF MEDICAL OFFICER↗
  • Sep 17, 26Compensation$59KBenjamin HohlCHIEF FINANCIAL OFFICER↗
  • Aug 17, 26Compensation$12KHelen Louise CollinsCHIEF MEDICAL OFFICER↗
  • Aug 4, 26Compensation$217KMika K Derynck↗
  • Aug 4, 26Compensation$697KMika K Derynck↗
  • Aug 4, 26Compensation$347KMika K Derynck↗
  • Aug 4, 26Compensation$460KMika K Derynck↗
  • Jul 17, 26Compensation$12KHelen Louise CollinsCHIEF MEDICAL OFFICER↗
  • Jul 17, 26Compensation$3KBenjamin HohlCHIEF FINANCIAL OFFICER↗
  • Jun 17, 26Compensation$12KHelen Louise CollinsCHIEF MEDICAL OFFICER↗

The full record holds 457 transactions and goes back to Jan 3, 23.

Its sector and its market

Enliven Therapeutics, Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From Enliven Therapeutics, Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow Enliven Therapeutics, Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
Series with incidents in the period; the chart shows what could be kept.
SEC records
763 documents on file, from Sep 11, 2019 to Oct 16, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.